estropipate and Atrophy

Topics: Adult; Amenorrhea; Atrophy; Clinical Trials as Topic; Estradiol Congeners; Estrogens; Estrogens, Conjugated (USP); Estrone; Ethinyl Estradiol; Female; Humans; Menopause; Middle Aged; Piperazines; Placebos; Pruritus Vulvae; Time Factors; Vagina

We studied a group of 398 patients who had been receiving estrogen replacement therapy since 1976. Group I consisted of 138 patients who received Premarin (conjugated equine estrogen, Ayerst) in two different dosages (0.625; 1.25 mg) and progestational agents such as Neogest (Norgestrel, Schering), Duphaston (Dydrogesterone, Duphar) 5 mg and Primolut N (Norethisterone, Schering) 5 mg, for a period ranging between 7 and 21 days. Group II consisted of 106 patients who received Harmogen (Piperazine Oestrone Sulphate, Abbott) in two different dosages (1.5 mg; 2.25 mg) with the above-mentioned progestational agents for a period ranging between 7 and 21 days. Group III consisted of 154 patients who received Progynova (Oestradiol Valerate, Schering) in two different dosages (1 mg; 2 mg) with the above-mentioned progestational agents for a period ranging between 7 and 21 days. When increasing dosages of estrogen with progestational agents were added for 7 days, this produced cystic hyperplasia of the endometrium. When the duration of progestational agents was increased to 10 days or more, a more atrophic and secretory endometrium resulted and there was no incidence of cystic hyperplasia.

Topics: Aged; Atrophy; Contraceptives, Oral, Combined; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dydrogesterone; Endometrium; Estradiol; Estrogens; Estrogens, Conjugated (USP); Estrone; Female; Humans; Hyperplasia; Levonorgestrel; Menopause; Middle Aged; Norethindrone; Norgestrel; Progestins; Time Factors